Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
11 - 20 of 139
Urinary stone disease (USD) is a common, chronic disorder that is seen more frequently in adolescence today than in the past. Current understanding of its impact on bone development and structure as well as dental health is not known. We will be evaluating bone and dental quality in 90 children/adolescents with USD and 90 healthy children/adolescents. The study requires: two to three visits for a total of three to four hours, that the participant be 5-21 years old, and compensation will be provided. If interested in participating contact the research coordinator at 267-226-6995.
This is an intergrated study of patients with congenital glycosylation disorder, including genetic conditions in the synthesis of glycoconjugates (congenital disorder of glycosyaltion), degradation of glycoconjugates (majority of lysosomal storage conditions), as well as the metabolism of glycoconjugates (such as certain inborn errors of metabolism that involved in nucleitide sugar metabolism, such as galactosemia, fructose intolarance, or certain glycogen storage conditions). Study methods includes glycomics analysis of body fluid or cells or tissues from patients, relevant metabolomics and genomics analysis.
The purpose of the TII study is to see how the prebiotic inulin changes the gut bacteria (microbiome) of children and young adults (ages 8-21) with IBD and determine if this dietary intervention can help reduce disease activity.
In patients with systemic juvenile idiopathic arthritis (sJIA), it is often difficult for physicians to distinguish between infection and inflammatory disease activity. The purpose of this study is to see if two biomarkers, called CP and PCT, can help physicians identify when patients have an infection versus a flare of their sJIA. This study involves two study visits, one at the time of a sJIA flare and one approximately 60 days after. We will ask participants to provide 3 teaspoons of blood for laboratory assessments, as well as answer brief questionnaires about their disease. The researchers will also review each participant's medical records for information regarding the history of their disease.
We are looking at how infants and young children breathe in different positions. This will help us understand how children with different types of lung hypoplasia breathe and how the lung changes and grows. To do this, we will measure regional lung ventilation by electrical impedance tomography (EIT) in three positions: lying on the back, right- and left-side in children with pulmonary hypoplasia and in healthy children without lung disease. EIT has been well established as a safe, non-invasive, radiation free method of assessing regional lung ventilation. There is no compensation available for this study.
CHOP is conducting a research study that will help make it possible to do future studies in children and family members both with and without problems with their brain and nervous system. This study involving collecting blood and other types of samples from participants along with medical information. These samples and the information will be stored in a "repository" for an indefinite amount of time. We'll use these tools in the future to create and develop new research studies that may help us find answers to some of these difficult illnesses.
The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients. We are looking to enroll, males or females ages 6 to 21 years old with a diagnosis of ulcerative colitis or indeterminate colitis who have started tofacitinib therapy prescribed by their primary gastroenterologist within the past 2 weeks or will be starting tofafacitinib within 1 month.
This clinical trial study uses a modified adeno-associated virus (AAV) to carry the human factor VIII gene to the liver. In the liver is where factor VIII protein is made. The study product, SPK-8011, is available only to participants in this research study. This product has not been approved yet for use in the general public. This will be the first hemophilia A gene transfer research study done in the United States. To learn more about the benefits and risks related to this study, please contact Dr. Lindsey George at (267) 425-0132.In order to participate in this study, you must be male, 18 years or older, have hemophilia A with FVIII activity levels less or equal to 2%, a history of bleeding that requires prophylaxis or on demand therapy, and no history of inhibitor to factor VIII. This study requires a number of visits over the course of 12 months. All costs related to participation in the study will either be covered or reimbursed by the Sponsor of the study, Spark Therapeutics, and participants will be compensated for their time.
The purpose of this research study is to find out if intranasal oxytocin (the hormone oxytocin, delivered through a nasal spray solution) will help with easy weight gain in children, adolescents, and adults with brain tumors and hypothalamic obesity syndrome. In children and adolescents with hypothalamic obesity syndrome, the production of oxytocin may be too low. Oxytocin is important for the body’s metabolism, or use of energy. Low oxytocin production could be a cause of easy weight gain in people with hypothalamic obesity syndrome.Participants will undergo a telephone screening and then an in-person screening visit to determine eligibility. Subjects will be randomized and begin 8 weeks of treatment with either Oxytocin or placebo. After a 4-week "washout", participants will cross-over to 8 weeks of treatment with the other condition (i.e., placebo or OXT). The proposed study has the potential to identify a rational, effective, and safe treatment strategy for a highly morbid condition for which no alternatives currently exist.
The Center for Pediatric Inflammatory Bowel Disease is conducting a research study to determine if a structured yoga program, in addition to standard medical treatment, improves quality of life in pediatric patients diagnosed with Inflammatory Bowel Disease. Participants between the ages of 10 and 17 will participate in 12 yoga classes, offered once a week at CHOP outpatient locations or in community settings. The classes include relaxation techniques, breathing exercises and yoga poses felt to be beneficial for a healthy digestive system. Participants also answer a series of questionnaires, four times over the course of the study.